Current research on treatment focuses on the targeted delivery of plectin for PC and the use of plectin-targeting agents for CRC and HCC.[57,74] Targeting agents against other family members of plakin, along with drug development, is highly desirable. The gene discussed is PLEC; the disease is hepatocellular carcinoma.